UNITED THERAPEUTICS Corp (UTHR) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
UNITED THERAPEUTICS’s revenue went from $1.6B in fiscal 2016 to $3.2B in fiscal 2025, growth of about 7.9% a year.
Net income in fiscal 2025 was $1.3B, a net margin of 41.9%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $3.2B and net income $1.2B.
Free cash flow was $1.0B in fiscal 2025 and positive in 9 of the 10 years shown.
The diluted share count rose 2% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2B | $3.2B | $2.9B | $2.3B | $1.9B | $1.7B | $1.5B | $1.4B | $1.6B | $1.7B | $1.6B |
| Gross profit | $2.8B | $2.8B | $2.6B | $2.1B | $1.8B | $1.6B | $1.4B | $1.3B | $1.4B | $1.6B | $1.5B |
| Operating income | $1.3B | $1.5B | $1.4B | $1.2B | $980M | $556M | $594M | -$188M | $805M | $815M | $1.1B |
| Net income | $1.2B | $1.3B | $1.2B | $985M | $727M | $476M | $515M | -$104M | $589M | $418M | $714M |
| EPS (diluted) | $26.49 | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 | $11.54 | $-2.39 | $13.39 | $9.31 | $15.25 |
| R&D | $703M | $550M | $481M | $408M | $323M | $540M | $358M | $1.2B | $358M | $265M | $148M |
| Revenue growth | — | +10.6% | +23.6% | +20.2% | +14.9% | +13.6% | +2.4% | −11.0% | −5.7% | +7.9% | +9.1% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.4B | $1.6B | $1.3B | $978M | $802M | $598M | $756M | -$207M | $778M | $474M | $644M |
| Capital spending | -$562M | -$520M | -$246M | -$230M | -$139M | -$121M | -$59M | -$84M | -$184M | -$86M | -$38M |
| Free cash flow | $867M | $1.0B | $1.1B | $748M | $664M | $477M | $696M | -$290M | $594M | $388M | $606M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $2.0B | $1.0B | $1.0B | $0 | $0 | — | — | — | — | $250M | $500M |
| Stock-based pay | $157M | $148M | $144M | $39M | $107M | $138M | $164M | $45M | -$26M | $74M | $12M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $2.9B | $3.3B | $3.0B | $2.8B | $1.9B | $1.8B | $1.5B | $1.4B | $927M | $1.1B |
| Debt | — | $0 | $300M | $700M | $800M | $800M | $800M | $855M | $508M | $250M | — |
| Equity | — | $7.1B | $6.4B | $6.0B | $4.8B | $4.0B | $3.4B | $2.8B | $2.8B | $2.1B | $1.9B |
| Total assets | — | $7.9B | $7.4B | $7.2B | $6.0B | $5.2B | $4.6B | $3.9B | $3.4B | $2.9B | $2.3B |
| Shares (diluted) | 45M | 48M | 48M | 50M | 48M | 47M | 45M | 44M | 44M | 45M | 47M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 86.3% | 87.9% | 89.2% | 88.9% | 92.2% | 92.7% | 92.7% | 91.9% | 87.8% | 93.9% | 95.5% |
| Operating margin | 41.4% | 46.9% | 47.9% | 50.9% | 50.6% | 33.0% | 40.0% | -13.0% | 49.5% | 47.2% | 66.4% |
| Net margin | 38.6% | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | 34.7% | -7.2% | 36.2% | 24.2% | 44.6% |
| FCF margin | 27.2% | 32.7% | 37.5% | 32.1% | 34.3% | 28.3% | 46.9% | -20.0% | 36.5% | 22.5% | 37.9% |
| ROIC | — | 16.4% | 15.9% | 13.7% | 13.4% | 9.4% | 11.4% | -3.3% | 19.0% | 18.8% | 38.6% |
| ROE | — | 18.8% | 18.6% | 16.5% | 15.2% | 12.0% | 15.2% | -3.8% | 21.1% | 19.9% | 38.6% |
Frequently asked questions
What is UNITED THERAPEUTICS’s annual revenue?
$3.2B in fiscal 2025 and $3.2B over the twelve months to September 30, 2026.
How much profit does UNITED THERAPEUTICS make?
Net income was $1.3B in fiscal 2025 (net margin 41.9%).
Is UNITED THERAPEUTICS’s revenue growing?
Yes: revenue rose 10.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.